SkinMedica Appoints Steve P. Loomis as Chief Financial Officer

CARLSBAD, Calif., May 12 /PRNewswire/ -- SkinMedica, Inc. today announced the appointment of Steve P. Loomis as Chief Financial Officer, effective May 10, 2010. Mr. Loomis succeeds Thomas Insley, who had been the Company's Chief Financial Officer since June 2003.

"We are delighted to welcome Steve to our management team. His more than twenty five years of experience in finance and operations, with a record of achievement in strong business growth and fiscal responsibility, will be of tremendous value as we continue to grow and bring new and innovative skin care products to the market," commented Mary Fisher, President and Chief Executive Officer. "I am very grateful to Tom for his invaluable contributions to SkinMedica, and for the solid foundation he has provided for our future. Tom will continue with the company for a transition period, working closely with Steve and myself."

Mr. Loomis was most recently the CFO and Vice President of Operations at CardioDynamics International Corporation, a publicly traded international medical device company, for thirteen years. While at CardioDynamics International Corporation, Mr. Loomis developed key business systems and processes to support revenue growth to more than $40 million and led many strategic financings for the Company, including its sale to SonoSite in August 2009. Previously, he was the Director of Financial reporting at Kinko's World Headquarters, a worldwide business service provider. Before that, he was Vice President, CFO and Treasurer of Terminal Data Corporation, a publicly traded international high technology manufacturing company.

Mr. Loomis graduated with honors from California State University at Northridge in 1985. He is a Certified Public Accountant and has served on the board of several for-profit and not-for-profit organizations.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. The Company markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products.

The Company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum™ and hallmark TNS Recovery Complex®. The formulations in SkinMedica's clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits.

SkinMedica's prescription products include VANIQA® (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin® Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.

SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.

TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.

SOURCE SkinMedica, Inc.